Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Company, has had its drug registration application for Polyethylene Glycol Electrolytes Powder (Ⅱ) accepted by the National Medical Products Administration. This chemical drug is designed for bowel cleansing before medical procedures like colonoscopies and surgeries. The company has invested approximately RMB4.74 million in the research and development of this drug series, highlighting its commitment to expanding its pharmaceutical offerings and potentially enhancing its market position.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and production of pharmaceutical products, with a market emphasis on innovative drugs and medical devices.
Average Trading Volume: 6,892,862
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.66B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.